VIOLIN Logo
VO Banner
Search: for Help
Vaxjo Home
Introduction
Statistics
News and Updates
Vaxjo Query
Selected Adjuvants
adamantylamide dipeptide vaccine adjuvant
aluminum hydroxide vaccine adjuvant
alhydrogel vaccine adjuvant
Data Submission
Data Exchange
Data Download
Documentation
FAQs
Disclaimer
Contact Us
UMMS Logo

Hsp65

Vaxjo ID 484       
Vaccine Adjuvant Name Hsp65       
Adjuvant VO ID VO_0005761
Description microbial derivative vaccine adjuvant that induces Th1-biased response       
Stage of Development Clinical Trial       
Location Licensed Japan       
Host Species for Testing Human       
Second Host Species for Testing Mouse       
Components heat shock protein 65       
Preparation vector constructed from recombinant L. lactis strain NCDO2118 that was able to secrete Mycobacterium leprae Hsp65       
Function Type: microbial derivative vaccine adjuvant. Target Receptor: Toll-like receptor 2 (TLR2) | Toll-like receptor 4 (TLR4). Induces Th1-biased immune profile. activation of APCs by TLR2/TLR4 signaling       
References
Bulut et al., 2005: Bulut Y, Michelsen KS, Hayrapetian L, Naiki Y, Spallek R, Singh M, Arditi M. Mycobacterium tuberculosis heat shock proteins use diverse Toll-like receptor pathways to activate pro-inflammatory signals. The Journal of biological chemistry. 2005; 280(22); 20961-20967. [PubMed: 15809303].
Gomes-Santos et al., 2017: Gomes-Santos AC, de Oliveira RP, Moreira TG, Castro-Junior AB, Horta BC, Lemos L, de Almeida LA, Rezende RM, Cara DC, Oliveira SC, Azevedo VA, Miyoshi A, Faria AM. Hsp65-Producing Lactococcus lactis Prevents Inflammatory Intestinal Disease in Mice by IL-10- and TLR2-Dependent Pathways. Frontiers in immunology. 2017; 8; 30. [PubMed: 28194152].
Okada et al., 2011: Okada M, Kita Y, Nakajima T, Kanamaru N, Hashimoto S, Nagasawa T, Kaneda Y, Yoshida S, Nishida Y, Nakatani H, Takao K, Kishigami C, Nishimatsu S, Sekine Y, Inoue Y, Matsumoto M, McMurray DN, De la Cruz EC, Tan EV, Abalos RM, Burgos JA, Saunderson P, Sakatani M. Novel therapeutic vaccine: granulysin and new DNA vaccine against Tuberculosis. Human vaccines. 2011; 7 Suppl; 60-67. [PubMed: 21546794].